XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber Buys 17,935 Shares

XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber acquired 17,935 shares of the company’s stock in a transaction that occurred on Thursday, April 3rd. The shares were acquired at an average cost of $25.24 per share, with a total value of $452,679.40. Following the purchase, the director now directly owns 16,524 shares of the company’s stock, valued at $417,065.76. This trade represents a -1,271.08 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

XOMA Stock Down 1.1 %

XOMA opened at $19.23 on Tuesday. The business’s fifty day simple moving average is $22.92 and its 200 day simple moving average is $26.51. XOMA Co. has a 52 week low of $18.35 and a 52 week high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The stock has a market cap of $230.36 million, a PE ratio of -5.53 and a beta of 1.00.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings data on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The firm had revenue of $8.70 million for the quarter, compared to the consensus estimate of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. As a group, research analysts expect that XOMA Co. will post -1.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

XOMA has been the topic of several recent analyst reports. StockNews.com cut XOMA from a “hold” rating to a “sell” rating in a report on Thursday, April 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $104.00 target price on shares of XOMA in a research note on Friday, March 28th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets lifted its holdings in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares during the last quarter. GAMMA Investing LLC raised its position in XOMA by 1,063.8% in the 1st quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,585 shares during the period. New York State Common Retirement Fund lifted its stake in XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares during the last quarter. Wells Fargo & Company MN lifted its stake in XOMA by 38.0% in the fourth quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,183 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in XOMA by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock valued at $205,000 after buying an additional 2,009 shares during the period. 95.92% of the stock is currently owned by institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.